AN2 Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $183.0M
- Price
- $4.85
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.34%
- Volume
- 365.3K
About
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Quick stats
Shares outstanding37.7M
Computed float25.1M
Float / shares66.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001880438
AI Summary
AI-generated1/12
minorbullishpartnership
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
AN2 Therapeutics announced an extension of Gates Foundation funding to support its tuberculosis research collaboration with GSK, focused on boron-based leucyl-tRNA synthetase (LeuRS) inhibitors.
The collaboration builds on AN2's boron chemistry platform, the same target family underlying epetraborole, ganfeborole, and the FDA-approved antifungal tavaborole.
No dollar amount was disclosed; the extension is a validation signal for the platform rather than a material pipeline or financial event.